Recent Finacing
Recent Raise
Scynexis collaborates with major pharma partners to discover and develop cyclophilin-inhibitor therapeutics, advancing a proprietary pipeline including SCY-635, a phase 2 hepatitis C candidate targeting host antiviral pathways.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors